Anti-CD20 chimeric antigen receptor T cell therapy - Cellular Biomedicine Group

Drug Profile

Anti-CD20 chimeric antigen receptor T cell therapy - Cellular Biomedicine Group

Alternative Names: Anti-CD20 CART cells; CAR-CD20 T cell therapy; CART20; CBM-C20.1; CBM-CD20 1; Genetically engineered lymphocyte therapy - Cellular Biomedicine Group

Latest Information Update: 25 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chinese PLA General Hospital
  • Developer Cellular Biomedicine Group; Chinese PLA General Hospital
  • Class CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Leukaemia; Lymphoma

Most Recent Events

  • 24 Aug 2017 Phase-I/II development is ongoing in China (NCT01735604)
  • 06 Jun 2017 Pharmacodynamic results from a preclinical study in Lymphoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 09 Aug 2016 Cellular Biomedicine Group has patent protection for Anti-CD20 chimeric antigen receptor T cell therapy in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top